Our group is focused on the development of gene therapy strategies for PNS and CNS against diseases caused by (i) mutations in specific genes like ALS, MLC, MPS-VII, SPG52, GNB1 Encephalopathy and Rett's Syndrome and (ii) by multifactorial causes such as Diabetes, Dementia or Alzheimer with the aim to apply them in clinical assays. Briefly, during 2021 we have generated 7 papers (3 D1 + 4 Q1), 1 patent, 1 Orphan Drug Designation (for MLC), defended 1 Master thesis and have in progress 1 Master thesis and 8 PhD thesis. Also, we have started 1 European (EJP-RD) and 4 national projects (RICORS, PID2020, PANDEMIAS, Proof of Concept), and have active 7 more (PTA, PID2019, RTC, CERVERA, La Lucha de Abril, Gen Rebelde, Fundacion Santander). In addition, our Vector Production Unit produced more than 200 batches for public groups and companies around the world. Last, due to the pandemia we are participating in 3 covid19 projects, published 1 paper, and worked with 6 biotechs.

Group Leader
Miguel Chillon Rodriguez

Principal Investigator (PI)
Assumpció Bosch Merino

Researchers
Juan Francisco Espinosa Parrilla, Beatriz Almolda Ardid, Angel Edo Salvador, Susana Miravet Delgado, Angela Sanchez Osuna

PhD Students
Rebeca Blanch Garcia, Joan Roig Soriano, Jon Esandi Jauregui, Laura Rodriguez Estevez, Sergi Verdes Franquesa, Andrea Onieva Salgado, Alejandro Brao Gonzalez, Ruben Guerrero Yague

Lab Technicians
Laia Rubio Ortega, Marc Cabrera Hurtado, Marina Tarres Mercader, Israel Alcazar Corrales, Elsa Ibarrola Carrasco, Javier del Rey Azpiry, Jorge Lunar Roldan

7

PUBLICATIONS

45

IMPACT FACTOR

6.45

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Mòdol-Caballero G, García-Lareu B, Herrando-Grabulosa M, Verdés S, López-Vales R, Pagès G, Chillon M, Navarro X, Bosch A
Specific expression of Glial-Derived Neurotrophic Factor in muscles as gene therapy strategy for Amyotrophic Lateral Sclerosis
Neurotherapeutics (2021), 18:1113-1126
DOI: doi: 10.1007/s13311-021-01025-6
IF: 7.62

T.A. Rubinstein, I. Reuveni, A. Hesin, A.K.Goldberg, H. Olauson, T.E. Larsson, C.R. Abraham, E. Zeldich, A. Bosch, M. Chillón, K.S. Hollander, A.Y. Orbach, G.W. Vainer, I. Wolf , and T. Rubinek.
A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy
Cancers (2021) Dec 15;13(24):6297
DOI: doi: 10.3390/cancers13246297
IF: 6.639

M Vogel-González, M Talló-Parra, V Herrera-Fernández, G Pérez-Vilaró, M Chillón, X Nogués-Solan, S Gómez-Zorrilla, I López-Montesinos, I Arnau-Barrés, M Luisa Sorli, J Pablo Horcajada, N García-Giralt, J Pascual, J Díez, R Vicente, R Güerri-Fernández
Low zinc levels at admission associates with poor clinical outcomes in SARS-CoV-2 infection
Nutrients (2021), 13(2):562: 1-13
DOI: doi: 10.3390/nu13020562
IF: 4.54

C. Griñán-Ferré, V. Izquierdo, A. Bellver-Sanchis, R. Corpás, J. Roig-Soriano, M. Chillón, C. Andres-Lacueva, M. Somogyvári, Csaba Sötti, C. Sanfeliu and M. Pallàs
The pleiotropic neuroprotective effects of resveratrol: from antioxidant to epigenetic inheritance modulator
Aging Research Reviews (2021) (67):101271: 1-24
DOI: doi: 10.1016/j.arr.2021.101271
IF: 10.62

E. Aubets , M. Chillon , C. J Ciudad , V. Noé
PolyPurine Reverse Hoogsteen Hairpins work as RNA species for gene silencing
International Journal of Molecular Sciences (IJMS) (2021) Sep 16;22(18):10025
DOI: doi: 10.3390/ijms221810025
IF: 5.92

RICORS-TERAV
Principal Investigator: Coordinator:Jose M Moraleda (FFIS). PI: Miguel Chillon
Agency: ISCIII. REDES DE INVESTIGACIÓN COOPERATIVA ORIENTADASA RESULTADOS EN SALUD (RICORS). RD21/0017/0008
Funding: 5,710,000.00€ (163,225.70 € for group)
Period: 1/12/2021 - 30/11/2024

A long-lasting anti-Covid-19 subcutaneous vaccine through a novel, industrially competitive and biologically safe nanomimetic concept (INVITA)
Principal Investigator: Coordinator: Antoni Villaverde (UAB). PI: Miguel Chillon
Agency: Programa PANDEMIAS
Funding: 295,000.00€
Period: 1/4/2021 - 31/3/2022

Terapia génica para esclerosis lateral amiotrófica dirigida a estimular la neuroprotección y la modulación de la neuroinflamación
Principal Investigator: Assumpcio Bosch
Agency: Ministerio Ciencia Innovación. Plan Nacional. PID2020-116735RB-I00
Funding: 117,975€
Period: 9/2021 - 8/2024

Recombinant HEBE: A chimeric Chronokine to rejuvenate the Brain
Principal Investigator: Juan F Espinosa
Agency: Programa proof of Concept.
Funding: 20,000 €
Period: 1/4/2021 - 31/3/2022

Secreted splicing variant of Klotho for treating bone disorders
Priority Number: EP21382465.9
Priority Date: 21/5/21
Applicants: 57,5%UAB, 15% ICREA, 7,5% VHIR, 20% UB

Neurosciences

Research Areas